LXEO vs. KYMR, BEAM, FUSN, INBX, SANA, NMRA, VIR, TARS, CGEM, and BCRX
Should you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Kymera Therapeutics (KYMR), Beam Therapeutics (BEAM), Fusion Pharmaceuticals (FUSN), Inhibrx (INBX), Sana Biotechnology (SANA), Neumora Therapeutics (NMRA), Vir Biotechnology (VIR), Tarsus Pharmaceuticals (TARS), Cullinan Therapeutics (CGEM), and BioCryst Pharmaceuticals (BCRX). These companies are all part of the "biological products, except diagnostic" industry.
Lexeo Therapeutics (NASDAQ:LXEO) and Kymera Therapeutics (NASDAQ:KYMR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations.
Lexeo Therapeutics currently has a consensus price target of $20.80, indicating a potential upside of 25.08%. Kymera Therapeutics has a consensus price target of $42.70, indicating a potential upside of 32.98%. Given Kymera Therapeutics' higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Lexeo Therapeutics.
In the previous week, Lexeo Therapeutics had 4 more articles in the media than Kymera Therapeutics. MarketBeat recorded 7 mentions for Lexeo Therapeutics and 3 mentions for Kymera Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.05 beat Kymera Therapeutics' score of 0.47 indicating that Lexeo Therapeutics is being referred to more favorably in the media.
Kymera Therapeutics received 34 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 48.19% of users gave Kymera Therapeutics an outperform vote.
Lexeo Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -194.67%. Kymera Therapeutics' return on equity of -31.92% beat Lexeo Therapeutics' return on equity.
Lexeo Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.
60.7% of Lexeo Therapeutics shares are owned by institutional investors. 4.5% of Lexeo Therapeutics shares are owned by insiders. Comparatively, 15.8% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Lexeo Therapeutics beats Kymera Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Lexeo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexeo Therapeutics Competitors List
Related Companies and Tools
